Predictive Value of Sarcopenia for Therapeutic Response and Prognosis in Patients with Acute Myeloid Leukemia.
10.19746/j.cnki.issn.1009-2137.2025.04.012
- Author:
Juan ZHAO
1
;
Jia LI
1
;
Ling-Ling QIAN
1
;
Zuo-Feng DING
1
;
Li ZHANG
2
Author Information
1. Department of Hematology, The Affiliated Hospital of Nantong University, Nantong 226001, Jiangsu Province, China.
2. Department of Hematology, Huai'an First People's Hospital, Huai'an, 223399, Jiangsu Province, China.
- Publication Type:Journal Article
- Keywords:
acute myeloid leukemia;
sarcopenia;
body composition;
therapeutic response;
prognosis
- MeSH:
Humans;
Sarcopenia/complications*;
Leukemia, Myeloid, Acute/diagnosis*;
Prognosis;
Male;
Female;
Induction Chemotherapy;
Middle Aged;
Body Mass Index;
Kaplan-Meier Estimate
- From:
Journal of Experimental Hematology
2025;33(4):1016-1022
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the effects of sarcopenia on therapeutic response and prognosis of newly diagnosed acute myeloid leukemia (AML) patients, and reveal its predictive value for the clinical outcomes of AML patients.
METHODS:A total of 122 AML patients who were initially diagnosed and treated with induction chemotherapy at the Department of Hematology in the Affiliated Hospital of Nantong University from January 2017 to December 2020 were included in this study. The sarcopenia was diagnosed by measuring body composition parameters with multifrequency bioelectrical impedance analyzer, and all AML patients were divided into sarcopenia and non-sarcopenia groups. Kaplan-Meier curves and log-rank test were used to compare the survival difference between the two groups. The relationship between sarcopenia and overall survival (OS) of AML patients was further determined by the univariate and multivariate Cox regression analysis.
RESULTS:Among 122 AML patients, 46 (37.7%) were diagnosed with sarcopenia before induction chemotherapy. The body mass index (BMI) of patients with sarcopenia was significantly lower than that of non-sarcopenia patients ( t =4.258, P <0.001), and the complete response (CR) and partial response (PR) rates of sarcopenia patients after induction chemotherapy were significantly lower than those of nonsarcopenia patients (χ2=6.348, P =0.042). Kaplan-Meier curves showed that sarcopenic patients had a shorter OS than non-sarcopenic patients, and the median OS of the two groups were 20.7 (95%CI : 12.6-27.8) months and 27.8 (95%CI : 22.3-31.9) months, respectively (χ2= 5.659, P =0.017). Subgroup analysis indicated that the median OS of sarcopenic and non-sarcopenic AML patients who received standard induction chemotherapy were 12.2 (95%CI : 5.4-24.7) months and 26.1 (95%CI : 16.7-35.4) months, respectively (χ2=3.949, P =0.047). The multivariate Cox regression analysis revealed that sarcopenia (HR=1.671, 95%CI : 1.034-2.701, P =0.036) was an independent predictor for poor prognosis in AML patients.
CONCLUSION:Sarcopenia is significantly associated with low response rate of induction chemotherapy and poor prognosis in AML patients, and it might be an useful tool for predicting the clinical outcome of AML patients.
